Oken MM - Search Results

1

Simultaneous presentation of relapsing Hodgkin's disease and treatment-related non-Hodgkin's lymphoma.

Perri RT, Allen JI, Oken MM, Limas C, Kay NE. Perri RT, et al. Among authors: oken mm. Med Pediatr Oncol. 1985;13(3):122-5. doi: 10.1002/mpo.2950130303. Med Pediatr Oncol. 1985. PMID: 3838792

2

Chronic lymphocytic leukemia in association with a second lymphoproliferative disorder: response to chemotherapy in two cases.

Gordon LI, Hrushesky W, Oken MM, Kay NE, Rydell RE. Gordon LI, et al. Among authors: oken mm. Med Pediatr Oncol. 1979;7(2):111-6. doi: 10.1002/mpo.2950070203. Med Pediatr Oncol. 1979. PMID: 388174

3

Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphomas and chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group pilot study.

O'Connell MJ, Colgan JP, Oken MM, Ritts RE Jr, Kay NE, Itri LM. O'Connell MJ, et al. Among authors: oken mm. J Clin Oncol. 1986 Feb;4(2):128-36. doi: 10.1200/JCO.1986.4.2.128. J Clin Oncol. 1986. PMID: 3511183 Clinical Trial.

4

The influential T cell in B-cell neoplasms.

Kay NE, Oken MM, Perri RT. Kay NE, et al. Among authors: oken mm. J Clin Oncol. 1983 Dec;1(12):810-6. doi: 10.1200/JCO.1983.1.12.810. J Clin Oncol. 1983. PMID: 6230420 Review.

5

Influence of treatment and response status on infection risk in multiple myeloma.

Perri RT, Hebbel RP, Oken MM. Perri RT, et al. Among authors: oken mm. Am J Med. 1981 Dec;71(6):935-40. doi: 10.1016/0002-9343(81)90303-x. Am J Med. 1981. PMID: 7315855

6

Low-dose ARA-C fails to enhance differentiation of leukaemic cells.

Perri RT, Weisdorf DJ, Oken MM. Perri RT, et al. Among authors: oken mm. Br J Haematol. 1985 Apr;59(4):697-701. doi: 10.1111/j.1365-2141.1985.tb07365.x. Br J Haematol. 1985. PMID: 3886002 Clinical Trial.

7

Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.

Oken MM, Kyle RA, Greipp PR, Kay NE, Tsiatis A, Gregory SA, Spiegel R J, O'Connell M J. Oken MM, et al. Leuk Lymphoma. 1996 Feb;20(5-6):447-52. doi: 10.3109/10428199609052427. Leuk Lymphoma. 1996. PMID: 8833401 Clinical Trial.

8

Enhanced T cell suppression is directed toward sensitive circulating B cells in multiple myeloma.

Perri RT, Oken MM, Kay NE. Perri RT, et al. Among authors: oken mm. J Lab Clin Med. 1982 Apr;99(4):512-9. J Lab Clin Med. 1982. PMID: 6460827

9

The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.

Oken MM, Leong T, Lenhard RE Jr, Greipp PR, Kay NE, Van Ness B, Keimowitz RM, Kyle RA. Oken MM, et al. Cancer. 1999 Sep 15;86(6):957-68. Cancer. 1999. PMID: 10491521 Clinical Trial.

10

T-cell subpopulations in multiple myeloma: correlation with clinical disease status.

Oken MM, Kay NE. Oken MM, et al. Br J Haematol. 1981 Dec;49(4):629-34. doi: 10.1111/j.1365-2141.1981.tb07273.x. Br J Haematol. 1981. PMID: 6976183

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

198 results

Search Page

Filters